Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aslan Pharmaceuticals Ltd ADR
(NQ:
ASLN
)
0.6000
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jul 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Aslan Pharmaceuticals Ltd ADR
< Previous
1
2
Next >
ASLAN Pharmaceuticals to Host Webcast on July 6, 2023, to Discuss Phase 2b Topline Data From TREK-AD Trial Evaluating Eblasakimab in Atopic Dermatitis
July 05, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Announces Publication in Clinical Immunology Highlighting Eblasakimab’s Unique Mechanism of Action in the Treatment of Atopic Dermatitis
June 23, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Enters Into a Strategic Licensing Deal With Zenyaku Kogyo for the Development and Commercialization of Eblasakimab in Japan
June 22, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
June 01, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Doses First Patient in Phase 2a Trial of Farudodstat in Alopecia Areata
May 18, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Presents New Data on Eblasakimab and Farudodstat in Two Late-Breaking Presentations at the 1st International Societies for Investigative Dermatology Meeting
May 15, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
April 28, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Announces Four Abstracts on Eblasakimab and Farudodstat, Including Two Late-Breakers, to be Presented at the 1st International Societies for Investigative Dermatology Meeting
April 24, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements
March 28, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 24, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals to Participate in Fireside Chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
March 22, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Announces Acceptance of Two Abstracts for Poster Presentation at the 1st International Societies for Investigative Dermatology Meeting
March 14, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change
March 10, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals to Host Virtual Research and Development Day on Novel DHODH Inhibitor Farudodstat for Alopecia Areata
March 08, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals to Advance Novel DHODH Inhibitor Farudodstat Into Phase 2 Clinical Testing as Potential First-In-Class Treatment for Alopecia Areata
February 28, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Announces $20M Private Placement Led by BVF Partners L.P. With the Potential to Receive Up to an Additional $80M
February 24, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Announces Completion of Recruitment in Phase 2b TREK-AD Study of Eblasakimab in Atopic Dermatitis Patients
February 24, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals and Thermo Fisher Scientific Announce Partnership to Manufacture High Concentration Formulation of Eblasakimab for Future Studies
January 03, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Announces Participation in January Investor Conferences
December 16, 2022
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Announces First Patient Screened in Study of Eblasakimab in Dupilumab Experienced Atopic Dermatitis Patients
December 15, 2022
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals to Participate in a Fireside Chat at 34th Annual Piper Sandler Healthcare Conference
November 21, 2022
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals to Participate in Jefferies London Healthcare Conference
November 08, 2022
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
October 28, 2022
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Two Late-Breaking e-Posters at the 51st Annual European Society for Dermatological Research Meeting
September 28, 2022
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.